HK1110602A1 - Compositions and methods of using angiopoietin-like protein - Google Patents

Compositions and methods of using angiopoietin-like protein

Info

Publication number
HK1110602A1
HK1110602A1 HK08104828.2A HK08104828A HK1110602A1 HK 1110602 A1 HK1110602 A1 HK 1110602A1 HK 08104828 A HK08104828 A HK 08104828A HK 1110602 A1 HK1110602 A1 HK 1110602A1
Authority
HK
Hong Kong
Prior art keywords
angiopoietin
protein
compositions
methods
Prior art date
Application number
HK08104828.2A
Other languages
English (en)
Chinese (zh)
Inventor
Stuart Bunting
Hans-Peter Gerber
Xiao Huan Liang
Original Assignee
健泰科生物技術公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健泰科生物技術公司 filed Critical 健泰科生物技術公司
Publication of HK1110602A1 publication Critical patent/HK1110602A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
HK08104828.2A 2004-07-20 2008-05-02 Compositions and methods of using angiopoietin-like protein HK1110602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58987504P 2004-07-20 2004-07-20
PCT/US2005/025650 WO2006014678A2 (fr) 2004-07-20 2005-07-19 Compositions et methodes d'utilisation de la proteine 4 analogue a l'angiopoietine

Publications (1)

Publication Number Publication Date
HK1110602A1 true HK1110602A1 (en) 2008-07-18

Family

ID=35787695

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08104828.2A HK1110602A1 (en) 2004-07-20 2008-05-02 Compositions and methods of using angiopoietin-like protein

Country Status (19)

Country Link
US (3) US7371384B2 (fr)
EP (1) EP1781698B1 (fr)
JP (2) JP5318412B2 (fr)
KR (1) KR20070061524A (fr)
CN (1) CN101080419B (fr)
AU (1) AU2005269758B2 (fr)
BR (1) BRPI0513477A (fr)
CA (1) CA2574791A1 (fr)
DK (1) DK1781698T3 (fr)
HK (1) HK1110602A1 (fr)
HU (1) HUE029170T2 (fr)
IL (4) IL180752A0 (fr)
LT (1) LT1781698T (fr)
MX (1) MX2007000783A (fr)
NO (1) NO342525B1 (fr)
NZ (2) NZ552957A (fr)
RU (2) RU2380411C2 (fr)
WO (1) WO2006014678A2 (fr)
ZA (1) ZA200701184B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2172482A1 (fr) * 2004-07-20 2010-04-07 Genentech, Inc. Inhibiteurs de protéines de type angiopoiétine 4, combinaisons, et leur utilisation
RU2380411C2 (ru) * 2004-07-20 2010-01-27 Дженентек, Инк. Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов
JP5366406B2 (ja) 2005-01-07 2013-12-11 レキシコン ファーマシューティカルズ インコーポレーテッド アンジオポエチン様タンパク質４（ａｎｇｐｔｌ４）に対するモノクローナル抗体
EP1919495A4 (fr) * 2005-08-19 2010-03-10 Univ St Louis Procedes et compositions permettant de traiter la radiosensibilite gastro-intestinale chez un sujet
AU2007233263A1 (en) * 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
CA2741034C (fr) * 2008-10-20 2021-06-22 Liposcience, Inc. Indices d'insulinoresistance a base de lipoproteine et procedes associes, systemes et programmes informatiques pour generer ceux-ci
SG10201406420XA (en) 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
CN106146591B (zh) * 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
WO2011089152A1 (fr) * 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour la préservation de l'intégrité de la barrière cellulaire de l'endothélium vasculaire
NO2575858T3 (fr) * 2010-06-05 2018-05-19
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
EP2661626B1 (fr) * 2011-01-08 2016-06-01 Astute Medical, Inc. Procédés et compositions pour diagnostiquer et pronostiquer une lésion rénale et une insuffisance rénale
CN102692496B (zh) * 2011-03-21 2015-10-28 上海市肿瘤研究所 Angptl4作为缺氧检测的标志物及其应用
CN102692500B (zh) * 2011-03-21 2015-06-10 上海市肿瘤研究所 Angptl4作为血清学检测肝癌转移的标志物及其应用
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
RU2711799C2 (ru) * 2011-06-21 2020-01-22 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RS61292B1 (sr) 2011-07-01 2021-02-26 Monsanto Technology Llc Postupci i jedinjenja za selektivnu regulaciju ekspresije belančevina
EP3399316A1 (fr) * 2011-08-08 2018-11-07 Nanyang Technological University Angiopoïétine-like 4 et son utilisation pour moduler la porosité des cellules
KR20140101397A (ko) 2011-12-09 2014-08-19 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
TWI641687B (zh) * 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2874708B1 (fr) * 2012-07-19 2020-04-08 Nanyang Technological University Un fragment du polypeptide de type angiopoïétine 4 pour l'utilisation dans la cicatrisation d'une plaie
AU2014233219B2 (en) * 2013-03-15 2018-02-22 Sumant S. CHUGH Methods for treatment of nephrotic syndrome and related conditions
SG10201801507RA (en) 2013-05-01 2018-03-28 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv and ttr expression
EP3021942A4 (fr) * 2013-07-19 2017-04-19 The Regents of The University of California Le facteur épidermique des globules gras du lait régule l'absorption des acides gras
KR102298476B1 (ko) 2013-12-24 2021-09-03 아이오니스 파마수티컬즈, 인코포레이티드 안지오포이에틴-유사 3 발현의 조절
US20170042870A1 (en) * 2014-02-17 2017-02-16 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
MX2017001746A (es) * 2014-08-07 2017-04-27 Novartis Ag Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
US10704057B2 (en) 2015-07-22 2020-07-07 Monsanto Technology Llc Methods and compositions for selective regulation of protein expression
MX2018005277A (es) 2015-11-06 2018-08-01 Ionis Pharmaceuticals Inc Modular la expresion de apolipoproteina (a).
WO2018002719A1 (fr) * 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions et méthodes pour l'édition génomique
JP7577654B2 (ja) * 2018-11-13 2024-11-05 リピゴン ファーマスーティカルス アー・ベー 脂肪酸代謝の調節に影響を与えるａｎｇｐｔｌ４オリゴヌクレオチド
CN115279402A (zh) * 2019-11-06 2022-11-01 西北大学 对ve-ptp磷酸酶的抑制保护肾免于缺血-再灌注损伤
AU2020399633A1 (en) 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
WO1999066041A1 (fr) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 proteines humaines secretees
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999032515A2 (fr) 1997-12-19 1999-07-01 Zymogenetics, Inc. Homologue de l'angiopoietine, adn le codant et procede de production dudit homologue
US20030099994A1 (en) 1998-03-02 2003-05-29 Millennium Pharamceuticals, Inc. Novel FDRG protein and nucleic acid molecules and uses therefor
JP2002516067A (ja) 1998-03-02 2002-06-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 新規ｆｄｒｇタンパク質および核酸分子、ならびにそのための用途
JP2000026767A (ja) 1998-05-01 2000-01-25 Daikin Ind Ltd 熱硬化性粉体塗料組成物
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2001057188A2 (fr) 2000-02-03 2001-08-09 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001053455A2 (fr) 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides associes
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
PT1623989E (pt) 1999-03-08 2007-09-25 Genentech Inc ''composições e métodos para o diagnóstico de tumores''
CA2370489A1 (fr) 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 49 proteines humaines secretees
DE60041367D1 (de) 1999-04-16 2009-02-26 Genentech Inc Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen
WO2001002429A2 (fr) 1999-07-02 2001-01-11 Bayer Aktiengesellschaft Angiopoietine 6 et ses utilisations
EP1210363A2 (fr) 1999-07-16 2002-06-05 Hyseq, Inc. Nouveaux procedes et materiaux des angiopoietines
US20030207348A1 (en) 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
EP1196576A2 (fr) 1999-07-20 2002-04-17 Curagen Corporation Polypeptides secretes et polynucleotides correspondants
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
WO2001077151A2 (fr) 2000-04-07 2001-10-18 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteines et d'acide nucleique fdrg et utilisation desdites molecules
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
EP1506398A4 (fr) 2001-03-27 2005-06-29 Human Genome Sciences Inc Proteines secretees humaines
EP1403367A4 (fr) 2001-06-08 2005-08-17 Sankyo Co Procede de test de medicament destine a traiter ou a prevenir des maladies telles que l'hyperlipemie
WO2003010205A1 (fr) 2001-07-26 2003-02-06 Duke University Medical Center Genes induits par hypoxie
CA2459219A1 (fr) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1539985A4 (fr) 2001-11-05 2006-06-28 Curagen Corp Polypeptides therapeutiques, acides nucleiques encodant ces polypeptides, et procedes d'utilisation
CN101905024A (zh) 2001-11-16 2010-12-08 杰南技术公司 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
JP5111729B2 (ja) 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (fr) 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf utilises comme marqueurs de modulation ppardelta
EP2172482A1 (fr) 2004-07-20 2010-04-07 Genentech, Inc. Inhibiteurs de protéines de type angiopoiétine 4, combinaisons, et leur utilisation
RU2380411C2 (ru) * 2004-07-20 2010-01-27 Дженентек, Инк. Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов
JP5366406B2 (ja) * 2005-01-07 2013-12-11 レキシコン ファーマシューティカルズ インコーポレーテッド アンジオポエチン様タンパク質４（ａｎｇｐｔｌ４）に対するモノクローナル抗体

Also Published As

Publication number Publication date
US8633155B2 (en) 2014-01-21
WO2006014678A2 (fr) 2006-02-09
US20060093606A1 (en) 2006-05-04
IL218357A (en) 2015-01-29
IL180752A0 (en) 2007-06-03
JP2011235179A (ja) 2011-11-24
IL218357A0 (en) 2012-04-30
NO342525B1 (no) 2018-06-04
AU2005269758A1 (en) 2006-02-09
RU2007106075A (ru) 2008-08-27
NZ552957A (en) 2011-06-30
EP1781698B1 (fr) 2016-07-06
RU2009137017A (ru) 2011-04-20
JP2008507531A (ja) 2008-03-13
IL206483A (en) 2011-11-30
LT1781698T (lt) 2016-09-26
CA2574791A1 (fr) 2006-02-09
ZA200701184B (en) 2008-07-30
US20100172915A1 (en) 2010-07-08
WO2006014678A3 (fr) 2006-06-22
IL209823A0 (en) 2011-02-28
NO20070950L (no) 2007-04-12
JP5318412B2 (ja) 2013-10-16
NZ592973A (en) 2013-01-25
KR20070061524A (ko) 2007-06-13
US7371384B2 (en) 2008-05-13
MX2007000783A (es) 2007-04-09
CN101080419B (zh) 2014-07-02
RU2380411C2 (ru) 2010-01-27
EP1781698A2 (fr) 2007-05-09
CN101080419A (zh) 2007-11-28
BRPI0513477A (pt) 2008-05-06
HUE029170T2 (en) 2017-03-28
IL206483A0 (en) 2010-12-30
DK1781698T3 (en) 2016-10-03
AU2005269758B2 (en) 2011-11-03
US20070054856A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
HK1110602A1 (en) Compositions and methods of using angiopoietin-like protein
HRP20182133T1 (hr) Pripravci koji sadrže azelastin i postupci njihove upotrebe
GB2414666B (en) Sanitizing composition and method of preparation
HK1119951A1 (en) Methods and compositions for oral administration of proteins
GB0422525D0 (en) Dermatological compositions and methods
IL191072A0 (en) Therapeutic compositions and methods
IL190885A0 (en) Immunogenic compositions and methods of use
EP1765260A4 (fr) Composition desinfectante et procede de preparation
IL182943A0 (en) Ovr110 antibody compositions and methods of use
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1786265A4 (fr) Nouvelles compositions et procedes de traitement
EP1762216A4 (fr) Composition pour préparation cosmétique et préparation cosmétique
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0504657D0 (en) Compositions and methods of treatment
EP1812032A4 (fr) Composition a base de facteur tissulaire et methodes associees
GB0517546D0 (en) Therapeutic methods and compositions
IL189956A0 (en) Methods and compositions for oral administration of proteins
SI1725610T1 (sl) Biocidni sestavki in postopki njihove izdelave
GB0428034D0 (en) Compositions and methods
GB0407993D0 (en) Therapeutic methods and compositions for use therein
GB0418363D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210717